We are live on
!
Find out more
NTC
North Tide Capital Portfolio holdings
AUM
$469M
1-Year Est. Return
6.57%
This Fund
S&P 500
This Quarter
Est. Return
+8.75%
1 Year Est. Return
+6.57%
3 Year Est. Return
+14.81%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.43B
AUM Growth
+$243M
(+20%)
Cap. Flow
+$127M
Cap. Flow
% of AUM
8.87%
Top 10 Holdings %
Top 10 Hldgs %
63.17%
Holding
29
New
5
Increased
9
Reduced
3
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bausch Health
BHC
|
+$63.8M |
| 2 |
Edwards Lifesciences
EW
|
+$48.8M |
| 3 |
SVU
SUPERVALU Inc.
SVU
|
+$47.9M |
| 4 |
VVUS
Vivus Inc
VVUS
|
+$46.3M |
| 5 |
Boston Scientific
BSX
|
+$44.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$82.3M |
| 2 |
AGN
Allergan Inc
AGN
|
+$77.8M |
| 3 |
Elevance Health
ELV
|
+$25.8M |
| 4 |
WCG
Wellcare Health Plans, Inc.
WCG
|
+$25M |
| 5 |
Viatris
VTRS
|
+$24.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 82.38% |
| 2 | Consumer Discretionary | 4.51% |
| 3 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SEM
1
DELISTED
Select Medical
SEM
| $218M | 15.22% |
25,891,200
| – | – |
|
2
Teva Pharmaceuticals
TEVA
$37.3B
| $157M | 11% |
3,000,000
| – | – |
|
|
SVU
3
DELISTED
SUPERVALU Inc.
SVU
| $69.9M | 4.89% |
1,214,286
+928,572
| +325% | +$47.9M |
|
|
TVTY
4
DELISTED
Tivity Health, Inc. Common Stock
TVTY
| $67.5M | 4.72% |
3,850,000
| – | – |
|
|
WCG
5
DELISTED
Wellcare Health Plans, Inc.
WCG
| $67.2M | 4.7% |
900,000
-350,000
| -28% | -$25M |
|
|
AMED
6
DELISTED
Amedisys
AMED
| $67M | 4.68% |
4,000,000
+800,000
| +25% | +$11.3M |
|
7
Orthofix Medical
OFIX
$468M
| $65.3M | 4.56% |
1,800,000
+672,700
| +60% | +$21.7M |
|
|
8
Elevance Health
ELV
$80.9B
| $64.6M | 4.52% |
600,000
-250,000
| -29% | -$25.8M |
|
|
9
Boston Scientific
BSX
$65.4B
| $63.9M | 4.47% |
5,000,000
+3,400,000
| +213% | +$44.2M |
|
|
10
Bausch Health
BHC
$1.8B
| $63.1M | 4.41% |
+500,000
| New | +$63.8M |
|
11
Quest Diagnostics
DGX
$23.3B
| $58.7M | 4.11% |
1,000,000
| – | – |
|
|
NUVA
12
DELISTED
NuVasive, Inc.
NUVA
| $53.4M | 3.73% |
1,500,000
| – | – |
|
|
13
Edwards Lifesciences
EW
$49.4B
| $51.5M | 3.6% |
+3,600,000
| New | +$48.8M |
|
|
VVUS
14
DELISTED
Vivus Inc
VVUS
| $47.9M | 3.35% |
+900,000
| New | +$46.3M |
|
|
WW
15
DELISTED
WW International
WW
| $40.3M | 2.82% |
+2,000,000
| New | +$42.8M |
|
16
Myriad Genetics
MYGN
$584M
| $38.9M | 2.72% |
1,000,000
| – | – |
|
|
KND
17
DELISTED
Kindred Healthcare
KND
| $34.6M | 2.42% |
1,500,000
| – | – |
|
|
AGN
18
DELISTED
Allergan Inc
AGN
| $33.8M | 2.37% |
200,000
-500,000
| -71% | -$77.8M |
|
|
MGLN
19
DELISTED
Magellan Health Services, Inc.
MGLN
| $31.1M | 2.18% |
500,000
| – | – |
|
|
ELOS
20
DELISTED
Syneron Medical Ltd
ELOS
| $31M | 2.17% |
3,000,000
+539,700
| +22% | +$5.83M |
|
|
MNTA
21
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $30.2M | 2.11% |
+2,500,000
| New | +$29.5M |
|
|
AFAM
22
DELISTED
Almost Family Inc
AFAM
| $24.1M | 1.68% |
1,090,500
+160,500
| +17% | +$3.49M |
|
23
Community Health Systems
CYH
$465M
| $22.7M | 1.59% |
605,000
| – | – |
|
|
GTIV
24
DELISTED
GENTIVA HEALTH SERVICES INC
GTIV
| $11.3M | 0.79% |
750,000
+250,000
| +50% | +$2.82M |
|
25
Accuray
ARAY
$30.8M
| $8.8M | 0.62% |
1,000,000
+500,000
| +100% | +$4.33M |
|
Similar funds
SD
DG
NBC
JWM
JPCCM
MCL
GIIO
FC
North Tide Capital's Q2 2014 Portfolio in Review
As of Q2 2014, North Tide Capital held 29 positions worth $1.43B, up 20% from $1.19B the previous quarter. Its ten largest holdings account for 63% of the portfolio.
North Tide Capital deployed $127M of net new capital in Q2 2014, opening 5 new positions and adding to 9 existing holdings. Its largest new stake was Bausch Health: 500,000 shares worth $63.1M.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 86% a quarter earlier, followed by Consumer Discretionary and Industrials.
On the sell side, the largest reduction was Allergan Inc, an estimated $77.8M trimmed.
- North Tide Capital's largest Q2 2014 buy was Bausch Health: 500,000 shares worth $63.1M.
- North Tide Capital added most to SUPERVALU Inc. in Q2 2014, an estimated $47.9M increase.
- North Tide Capital's biggest Q2 2014 reduction was Allergan Inc, cutting an estimated $77.8M.
- North Tide Capital fully exited Allergan plc in Q2 2014, selling an estimated $82.3M.
- North Tide Capital's ten largest holdings make up 63% of its $1.43B portfolio in Q2 2014.
- North Tide Capital opened 5 new positions and closed 3 in Q2 2014.
- North Tide Capital's portfolio value rose 20% quarter-over-quarter to $1.43B.
Based on North Tide Capital's 13F filing for Q2 2014, filed 14 Aug 2014.